Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jul;166(2):254-259.
doi: 10.1111/bjh.12852. Epub 2014 Mar 25.

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group

Katherine Tarlock #  1   2 , Todd A Alonzo #  3   4 , Pilar Palomo Moraleda  5 , Robert B Gerbing  4 , Susana C Raimondi  4   6 , Betsy A Hirsch  4   7 , Yaddanapudi Ravindranath  4   8 , Beverly Lange  4   9 , William G Woods  4   10 , Alan S Gamis  4   11 , Soheil Meshinchi  1   2   4
Affiliations
Clinical Trial

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group

Katherine Tarlock et al. Br J Haematol. 2014 Jul.

Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a rare subtype associated with FLT3-internal tandem duplication (ITD) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without FLT3-ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and without FLT3-ITD had an OS of 40% and 27% respectively (P > 0·9), demonstrating that t(6;9) is a high-risk cytogenetic feature in paediatric AML and its clinical impact is independent of the presence of FLT3-ITD.

Keywords: FLT3-ITD; acute myeloid leukaemia; clinical outcome; paediatric; t(6; 9)(p23; q34).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical outcome of patients with t(6;9) based on the presence or absence of FLT3-ITD: Patients with t(6;9) have a worse overall survival (A) and Relapse Risk (B) in contrast to those without t(6;9). Outcome for patients with t(6;9) is similar to those with high-risk cytogenetics (C and D). In patients with t(6;9) those with and without FLT3-ITD have similar survival and relapse risk (E and F). FLT3-ITD, FLT3 internal tandem duplication; CR, complete remission; CBF AML, core-binding factor acute myeloid leukemia; cyto, cytogenetics;
See this image and copyright information in PMC

References

    1. Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007;109:2264–5. author reply 2265. - PubMed
    1. Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis AS. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer. 2012;118:761–769. - PubMed
    1. Gamis AS, Alonzo TA, Gerbing RB, Aplenc R, Sung L, Meshinchi S, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, Davies SM, Smith FO. Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children’s Oncology Group Phase III Trial, AAML0531. Blood (ASH Annual Meeting Abstracts) 2010;116:182.
    1. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, deGraaf SS, van den Berg E, Burnett AK, Gibson BE. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML10 and 12. Journal of Clinical Oncology. 2010;1:2674–2681. - PubMed
    1. Ishiyama K, Takami A, Kanda Y, Nakao S, Maeda T, Naoe T, Tanigcuhi S, Kawa K, Nagamura T, Tabuchi K, Atsuta Y, Sakamaki H. Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant. Leukemia. 2012;26:1416–1419. - PubMed

Publication types

MeSH terms